# Docking Study of Buspirone Analogues to a Serotonine Transporter Model. 

Małgorzata Jarończyk ${ }^{a}$, Karol Wołosewicz ${ }^{\text {b }}$, Marta Szymańska ${ }^{b}$, Aleksander P. Mazurek ${ }^{a}$, Andrzej Bojarski ${ }^{d}$, Mari Gabrielsen ${ }^{\text {c }}$, Ingebrigt Sylte ${ }^{\text {c }}$, Zdzisław Chilmonczyk ${ }^{\text {a }}$<br>${ }^{a}$ National Institute of Medicines, Chelmska 30/34, 00-725 Warsaw<br>${ }^{b}$ Institute of Chemistry, University of Bialystok, Piłsudskiego 11/4, 15-443 Bialystok<br>${ }^{c}$ Institute of Medical Biology, Faculty of Health Science, University of Tromsø, N9037 Tromsø, Norway<br>${ }^{d}$ Institute of Pharmacology, Smętna 12, 31-343 Kraków<br>e-mail: chilmon@il.waw.pl

6-Nitroquipazine has been known as one of the most potent and selective inhibitors of the serotonin transporter (SERT). In the present study we examined several buspirone analogues, with known SERT affinities, containing quipazine or 6-nitroquipazine moieties in the aromatic part of a molecule. The compounds were docked to SERT and analyzed using molecular modelling methods. The SERT model was based on the crystal structure of a bacterial homologue of SERT, the leucine transporter (LeuT ${ }_{\text {Aa }}$ ).


$$
\mathrm{R}=\mathrm{H} ;-\mathrm{NO}_{2}
$$

The docking indicated that the imide moieties of the high affinity ligands remained in close contacts with - SERT Tyr95 (THM1) and Ser438 (THM8). In such an orientation of nitrated (low affinity) ligands, the nitro groups were in close steric contacts with the hydrophobic amino acids $\mathrm{Val}^{343}$ and Lue ${ }^{344}$ in TMH6. It also appeared that nitro groups can occupy the binding place of imide carbonyls. Thus during docking of nitrated ligands to the SERT narrow binding site possible destabilising steric contacts between ligand's polar groups and SERT hydrophoobic amino acids were observed.

This study was partly supported by the PNRF-103-AI-1/07 project "Creating an academia based platform to discover substances acting on serotonergic or glutamatergic system as potential new antidepressant or anxiolytic drugs".

